De-risking drug development: Key chemistry, manufacturing, and controls (CMC) and physiologically based pharmacokinetic (PBPK) approaches in early development
November 22, 2024 In drug development, early strategic planning is crucial to minimizing risks, optimizing…
CertaraNovember 22, 2024
Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design
How an augmented definitive screening design identified CAR-T and lymphodepletion regimens with 2.37-fold higher odds…
CertaraNovember 20, 2024
Why clinical pharmacology & pharmacometrics should collaborate
A symbiosis between a modeler and a trialist is often required to develop a model-informed…
CertaraNovember 8, 2024
